San Diego-based Amplyx Pharmaceuticals, which is developing antifungal agents that treat life-threatening fungal infections, has raised $40.5 million in Series B funding. RiverVest Venture Partners led the round with participation from other investors that included New Enterprise Associates and BioMed Ventures. In conjunction with the funding, Dr. Niall O’Donnell, managing director at RiverVest Venture Partners and Ed Mathers, a partner at New Enterprise Associates, were added to Amplyx’s board of directors.